1 active not recruiting, 1 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
Follow IC-MPGN: new trials by email Literature Review of IC-MPGN trials Research Report on IC-MPGN
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Placebo, iptacopan - IC-MPGN | Phase 3 | Recruiting | Novartis Pharmaceuticals | 106 | 2023-10-02 | 2026-07-13 |
| An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan - C3G, IC-MPGN | Phase 3 | Active not recruiting | Apellis Pharmaceuticals, Inc. | 100 | 2023-05-29 | 2026-04-02 |
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Pegcetacoplan, Placebo - C3G, IC-MPGN | Phase 3 | Completed | Apellis Pharmaceuticals, Inc. | 124 | 2021-11-12 | 2026-01-29 |
Glomerulonephritis, Membranoproliferative (2) · Proteinuria (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Male Urogenital Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Nephritis (2) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1) · Urination Disorders (1) · Urological Manifestations (1)
pegcetacoplan (2) · iptacopan (1)
Apellis Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (1)
Argentina (3) · Brazil (3) · Czechia (3) · France (3) · Israel (3) · Italy (3) · Japan (3) · Netherlands (3) · South Korea (3) · Spain (3) · Switzerland (3) · United Kingdom (3) · United States (3) · Australia (2) · Belgium (2)
2023 (1)